H2R Tuesday, 12/04/18 10:46:35 AM Re: None Post # of 196 Interesting comment on SA's https://seekingalpha.com/news/3414289-portolas-cerdulatinib-continues-show-positive-action-mid-stage-lymphoma-study Quote:Fightdoctor This was a positive study in a drug that may produce something for Portola investors. However, the main reason to be in this stock is for the drug Andexxa, the reversal agent for Eliquis and Xarelto. The drug is approved but the method of producing it, referred to as Gen 1 is inefficient. Portola is only offering this life saving drug to about 160 US hospitals at this time. Investors are awaiting two decisions. The CHMP decision for the European Union is due next week and the FDA approval decision of the Gen 2 method of producing is due by Dec. 31. Portola has stock piled over $300,000,000 of the Gen. 2 drug in anticipation of that approval. The drug is being manufactured by a very reliable Swiss company, Lonza. They have an excellent record of bringing drugs through regulatory processes. The stock as been beaten down with a very large short interest. That has presented an uncommon opportunity to get in on a company at a low price. I am a long term believer in Portola and Andexxa. There are lots of opinions as to when this company share price will take off and how high it will go. But, based on the action at the time of previous, less momentous, announcements I am expecting two large pops soon.